Newsfile Corp
03 Sept 2026, 18:45 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
FDA briefing documents revealed that Capricor modified its statistical analysis plan without submitting it for FDA review or agreement prior to the BLA submission. — Failure to agree on a statistical analysis plan with the FDA is a critical regulatory red flag that significantly increases the risk of BLA rejection.
-0.90A securities class action lawsuit has been filed against Capricor Therapeutics alleging investor losses between December 17, 2025, and July 26, 2026. — Class action lawsuits create potential long-term financial liabilities and signal governance or transparency issues to the market.
-0.40Capricor's stock price suffered a single-day decline of 64% on July 27, 2026, following the release of FDA briefing documents. — While this is a historical event, it confirms the market's extreme negative reaction to the underlying regulatory issues.
-0.20Which stocks this story touches
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
3h ago
